Catherine Pickering, CEO
Catherine holds a PhD in Medicinal Chemistry from The Institute of Cancer Research, London and an MBA from Henley Management College, UK. She is an experienced deal maker with broad transaction experience including licensing (in- and out licensing, option deals, and strategic collaborations) and M&A. During her time at Merck where she lead the global oncology and immuno-oncology licensing and business development function she was also part of the oncology franchise leadership team, a small cross functional team responsible for creating the strategy for the oncology business. She has also held business development and alliance management positions in small biotech and started her career in technology transfer at The Institute of Cancer Research. Her longstanding experience in the healthcare industry gives her a wide network across research institutions and with c-levels in biotech and pharma.
Lars van der Veen, COO
Lars holds a PhD in homogeneous catalysis (cum laude) from the University of Amsterdam. He is an experienced project and alliance manager with demonstrated leadership in pre-clinical and clinical development. He has managed >25 alliances for in-licensed and out-licensed products of both biologics and small molecules, driving governance, delivery of results and issue resolution. As a medicinal chemist and team leader he delivered clinical candidates and lead compounds for different therapeutic areas including oncology. He brings a wide network in academia and c-levels in biotech. Lars has previously worked at Solvay Pharmaceuticals, Organon, Boehringer-Ingelheim and Merck.
Zoë Johnson, Head Translational Research & Early Development
Zoë holds a PhD in Pharmacology from King’s College London, UK. Zoë has more than 15 years of experience in the biopharmaceutical industry in the UK and Europe where she has worked across a range of therapy areas including oncology, autoimmune & inflammatory diseases and allergy. Her main area of expertise is in building preclinical pharmacology packages to support IND filings, as well as providing bioanalytical support to late stage clinical development programs. Zoë is an experienced project leader and has successfully led both small and large molecule projects through late stage preclinical development. Zoë has previously worked at UCB, Merck and Novimmune and is based in Geneva, Switzerland.